Chadé Severin

Chadé Severin represents private and public companies on a wide range of corporate and securities law matters, including mergers and acquisitions, securities law compliance and other general corporate matters.

Ms. Severin’s representations include:

• Stemline Therapeutics in its sale to Menarini Group for up to $677 million;
• Gilead Sciences in its $4.9 billion acquisition of Forty Seven;
• ArQule in its sale to Merck for $2.7 billion;
• Carbonite in its sale to OpenText for $1.42 billion;
• Achillion in its sale to Alexion for up to $1.225 billion;
• Alder BioPharmaceuticals in its sale to Lundbeck for up to $1.95 billion;
• Array BioPharma in its $11.4 billion sale to Pfizer;
• Carbonite in its $618.5 million acquisition of Webroot;
• Armstrong Flooring Inc. in the sale of its wood flooring business to American Industrial Partners;
• Juno Therapeutics in its $9 billion acquisition by Celgene;
• Ultragenyx in its successful topping bid for Dimension Therapeutics;
• Gilead in its $11.9 billion acquisition of Kite Pharma;
• Merrimack Pharmaceuticals in its asset sale to Ipsen S.A. for up to $1.025 billion;
• Tobira Therapeutics in its acquisition by Allergan for up to $1.7 billion; and
• Qlik Technologies in its $3 billion acquisition by Thoma Bravo.

Before attending law school, Ms. Severin worked for Google at its California headquarters.